Emergent BioSolutions (EBS) PT Raised to $71 at Chardan Capital Markets

Go back to Emergent BioSolutions (EBS) PT Raised to $71 at Chardan Capital Markets

Emergent BioSolutions (EBS) Tops Q4 EPS by 13c

February 21, 2019 4:43 PM EST

Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.75, $0.13 better than the analyst estimate of $0.62. Revenue for the quarter came in at $270.7 million versus the consensus estimate of $270.03 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

... More